Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its ...

On World Cancer Day, Servier reaffirms its commitment to the fight against cancer by focusing on oncology as a central part of its Research & ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.

Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence could improve its drug development processes. The two ...